Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Head And Neck Squamous Cell Carcinoma (HNSCC): Update Bulletin #1 [June 2018]

Product Code:
Publication Date:
June 2018

Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC), including: the release of data from a Phase Ib/II trial of Lenvima (lenvatinib; Eisai) plus Keytruda (pembrolizumab; Merck & Co.) in patients with metastatic HNSCC at the American Society for Clinical Oncology (ASCO) Annual Meeting 2018; the presentation of a preliminary safety analysis from the Phase III REACH trial of avelumab (Bavencio; Merck Group/Pfizer) combined with Erbitux (cetuximab; Eli Lilly/Merck Group) and radiotherapy at ASCO 2018; the FDA approval of an application from Bristol-Myers Squibb (BMS) to update the dosing schedule for Opdivo (nivolumab) to once every four weeks for HNSCC.

Business Questions:

• How do KOLs interpret the Phase Ib/II data for Lenvima plus Keytruda presented at ASCO 2018?
• Based on the available data, what are KOL expectations for the tolerability profile for Lenvima in combination with Keytruda in metastatic HNSCC?
• What is the overall outlook for Lenvima plus Keytruda as a potential therapy for HNSCC?
• How do KOLs view the rationale for combining avelumab with Erbitux and radiotherapy in the treatment of locally advanced HNSCC?
• What are KOL views on the design of the Phase III REACH trial of avelumab plus Erbitux/radiotherapy, versus standard of care therapy, in locally advanced HNSCC?
• In which patients with locally advanced disease is avelumab in combination with Erbitux and radiotherapy most likely to be selected for?
• How do KOLs view the revised dosing schedule for Opdivo in the treatment of HNSCC and will it result in any increase in the overall use of this PD-1 inhibitor?


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved